CGS’s result was largely pre-announced with rev of $19.5m and EBIT -$0.2m. Clinical trial segment rev was $17.1m, -18% vs pcp impacted by c.$3.3m rev deferred to FY24+.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.